このページの翻訳は実験的なもので、現在開発中です。お待ちしております！

Comera Life Sciences Holdings マネジメント

マネジメント基準チェック /04

現在、CEO に関する十分な情報がありません。

主要情報

Michael Campbell

最高経営責任者

n/a

報酬総額

CEO給与比率	n/a
CEO在任期間	2.3yrs
CEOの所有権	0.1%
経営陣の平均在職期間	データなし
取締役会の平均在任期間	2.8yrs

経営陣の近況

Recent updates

Comera Life Sciences Holdings (NASDAQ:CMRA) Is In A Good Position To Deliver On Growth Plans

May 27

CEO報酬分析

Comera Life Sciences Holdings の収益と比較して、Michael Campbell の報酬はどのように変化したか？
日付	総報酬	給与	会社業績
Sep 30 2023	n/a	n/a	-US$9m
Jun 30 2023	n/a	n/a	-US$10m
Mar 31 2023	n/a	n/a	-US$18m
Dec 31 2022	US$1m	US$202k	-US$18m

報酬と市場: Michaelの総報酬がUS市場の同規模の企業と比較して妥当かどうかを判断するにはデータが不十分です。

報酬と収益: Michaelの報酬と会社の業績を比較するにはデータが不十分です。

CEO（最高経営責任者

Michael Campbell (55 yo)

2.3yrs

在職期間

US$1,224,009

報酬

Mr. Michael G. Campbell, CPA, serves as Chief Executive Officer, Chief Financial Officer and Principal Accounting Officer of Comera Life Sciences Holdings, Inc. since January 31, 2024 and has been its Chie...

取締役

名称	ポジション	在職期間	報酬	所有権
David Soane	Co-Founder & Member of Scientific Advisory Board	no data	データなし	12.08% $ 92.8k
James Sherblom	Independent Director	3.5yrs	US$81.25k	1.47% $ 11.3k
John Sorvillo	Chairman of Scientific Advisory Board	no data	US$520.24k	データなし
V. Lawlis	Member of Scientific Advisory Board	no data	データなし	データなし
Barbara Finck	Scientific Advisory Board	1.5yrs	US$48.33k	0.17% $ 1.3k
John Carpenter	Member of Scientific Advisory Board	no data	データなし	データなし
Alan Herman	Member of Scientific Advisory Board	no data	データなし	データなし
John Yee	Scientific Advisory Board	1.5yrs	US$48.33k	データなし
Andrew Jones	Member of Scientific Advisory Board	no data	データなし	データなし
Kirsten Flowers	Independent Director	2.9yrs	US$58.54k	0.072% $ 555.0
Sirshendu Banerjee	Independent Director	2.8yrs	US$62.92k	0.094% $ 723.9
Edward Sullivan	Independent Director	2.8yrs	US$62.92k	0.064% $ 491.7

2.8yrs

平均在職期間

68yo

平均年齢

経験豊富なボード: CMRAの取締役会は経験豊富ではない ( 2.8年の平均在任期間) ため、新しい取締役会が必要であると考えられます。

Comera Life Sciences Holdings マネジメント

マネジメント 基準チェック /04

主要情報

経営陣の近況

Comera Life Sciences Holdings, Inc. Announces Chief Executive Officer Changes

Comera Life Sciences Holdings, Inc. Appoints Dorothy Clarke to Board of Directors

Comera Life Sciences Holdings, Inc., Annual General Meeting, Aug 31, 2023

Comera Life Sciences Holdings, Inc. Announces Board Resignations

High number of new and inexperienced directors

Comera Life Sciences Appoints Janice Marie Mccourt as Chief Business Officer

Recent updates

The Nasdaq Stock Market to Delist the Common Stock of Comera Life Sciences Holdings

Comera Life Sciences Holdings, Inc. Announces Chief Executive Officer Changes

Comera Life Sciences Holdings, Inc.(OTCPK:CMRA) dropped from NASDAQ Composite Index

Comera Life Sciences Holdings Receives Notice from the Nasdaq Stock Market

Comera Life Sciences Holdings, Inc. Appoints Dorothy Clarke to Board of Directors

Second quarter 2023 earnings released: US$0.078 loss per share (vs US$1.14 loss in 2Q 2022)

New major risk - Shareholder dilution

Comera Life Sciences Holdings Receives Non-Compliance Notice From The Nasdaq Stock Market LLC

Comera Life Sciences Holdings, Inc. announced that it has received $4.069993 million in funding

Comera Life Sciences Holdings, Inc. Announces Publication of Study Reinforcing Caffeine's Viscosity Reducing Capabilities

Second quarter 2023 earnings released: US$0.078 loss per share (vs US$1.14 loss in 2Q 2022)

Comera Life Sciences Holdings, Inc., Annual General Meeting, Aug 31, 2023

Comera Life Sciences Holdings, Inc. Significantly Expands Intellectual Property Portfolio Strengthening the Proprietary SQore(TM) Platform

Comera Life Sciences Holdings, Inc. announced that it expects to receive $4.1 million in funding

New major risk - Share price stability

Comera Life Sciences Holdings Receives A Determination Letter from Nasdaq Regarding Market Value of Listed Securities

First quarter 2023 earnings released: US$0.13 loss per share (vs US$3.09 loss in 1Q 2022)

Comera Life Sciences Holdings Receives Notice from Nasdaq Regarding Not in Compliance with the Minimum Bid Price Requirement

Full year 2022 earnings released: US$1.76 loss per share (vs US$1.40 loss in FY 2021)

Comera Life Sciences Holdings, Inc. Announces Board Resignations

High number of new and inexperienced directors

Comera Life Sciences Holdings Receives a Non-Compliance Letter from the Listing Qualifications Department Staff of Nasdaq

Third quarter 2022 earnings released

Third quarter 2022 earnings released

Comera Life Sciences Appoints Janice Marie Mccourt as Chief Business Officer

Comera Life Sciences Holdings, Inc. Announces Favorable Preclinical Results of Lead SQore Excipient in SEQURUS-2 Study

Comera Life Sciences rises on positive preclinical data from Sequrus study

Comera life sciences expands woburn operations

Independent Director recently bought US$102k worth of stock

Comera Life Sciences Holdings, Inc. announced that it expects to receive $15 million in funding from Arena Business Solutions Global SPC II, Ltd

Comera Life Sciences announces up to $15M purchase agreement with Arena

Second quarter 2022 earnings released

Comera Life Sciences to Present Topline Results of SEQURUS-2 Study at 14th Annual Bioprocessing Summit

Comera Life Sciences GAAP EPS of -$1.14, revenue of $0.15M

Comera Life Sciences Announces Favorable Preclinical Topline Safety Results of Lead SQore Excipient

Comera Life Sciences Holdings, Inc. Appoints Michael Campbell as Executive Vice President